Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

ABSTRACT: HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

PROVIDER: PRJNA413052 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6129070_1.fastq.gz	Fastqsanger.gz
	SRR6129070_2.fastq.gz	Fastqsanger.gz
	SRR6129080_1.fastq.gz	Fastqsanger.gz
	SRR6129080_2.fastq.gz	Fastqsanger.gz
	SRR6129071_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 54

Similar Datasets

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

Project description:Rhabdomyosarcoma (RMS) is an aggressive and difficult to treat cancer characterized by a muscle-like phenotype. Although the average 5-year survival rate is 65% for newly diagnosed RMS, the treatment options for metastatic disease are limited in efficacy, with the 5-year survival rate plummeting to 30%. Heterogenous nuclear ribonucleoprotein H1 (HNRNPH1) is an RNA-binding protein that is highly expressed in many cancers, including RMS. To determine the role HNRNPH1 plays in RMS tumorigenesis, we investigated its expression and effect on growth in 3 cellular models of RMS: RD, RH30, and RH41 cells. Upon knockdown of HNRNPH1, growth of all cell lines was dramatically reduced, most likely through a combination of apoptosis and cell cycle arrest. We then recapitulated this finding by performing in vivo xenograft studies, in which knockdown of HNRNPH1 resulted in a striking reduction in tumor formation and growth. We used RNA sequencing to identify changes in gene expression after HNRNPH1 knockdown and found altered splicing of some oncogenes. Our data show that HNRNPH1 may be an important molecular target for the development of future RMS therapy.

2018-02-02 | GSE104559 | GEO

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.

Project description:Rhabdomyosarcoma (RMS) is an aggressive and difficult to treat cancer characterized by a muscle-like phenotype. Although the average 5-y survival rate is 65% for newly diagnosed RMS, the treatment options for metastatic disease are limited in efficacy, with the 5-y survival rate plummeting to 30%. Heterogenous nuclear ribonucleoprotein H1 (HNRNPH1) is an RNA-binding protein that is highly expressed in many cancers, including RMS. To determine the role HNRNPH1 plays in RMS tumorigenesis, we investigated its expression and effect on growth in three cellular models of RMS: RD, RH30, and RH41 cells. Upon knockdown of HNRNPH1, growth of all cell lines was reduced, most likely through a combination of apoptosis and cell cycle arrest. We then recapitulated this finding by performing in vivo xenograft studies, in which knockdown of HNRNPH1 resulted in a reduction of tumor formation and growth. We used RNA sequencing to identify changes in gene expression after HNRNPH1 knockdown and found altered splicing of some oncogenes. Our data contribute to understanding the role of HNRNPH1 in RMS development.

| S-EPMC5833419 | biostudies-literature

RIP-seq of DDX5 in rhabdomyosarcoma cells

Project description:Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood characterized by the inability to exit the proliferative myoblast-like stage. Here, we identified the DEAD box RNA helicase 5 (DDX5) as a potential therapeutic target to inhibit alveolar rhabdomyosarcoma (ARMS) growth. We show that DDX5 is overexpressed in alveolar RMS cells, demonstrating that its depletion drastically decreases ARMS viability and slows tumor growth in xenograft models. Mechanistically, we provide evidence that DDX5 functions upstream the G9a/AKT survival signalling pathway, by modulating G9a protein stability

2022-08-22 | GSE175455 | GEO

Transcriptional profiling by RNA-seq in siDDX5 Rh30 rhabdomyosarcoma cells

2022-08-22 | GSE152358 | GEO

miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells

Project description:This SuperSeries is composed of the following subset Series: GSE35491: miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells (Illumina) GSE35606: miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells (miRNA) Refer to individual Series

2012-04-01 | E-GEOD-35921 | biostudies-arrayexpress

Gene Expression in Human Rhabdomyosarcoma

Project description:Gene expression analysis identified unique transcriptional changes in rhabdomyosarcoma when compared with normal muscle. Our studies focused on a gene called VANGL2 that regulated growth and self-renewal in embryonal rhabdomyosarcoma.

2018-03-06 | GSE108022 | GEO

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma The expression profiles of TC32 Ewing sarcoma cells were determine 48 hours post siRNA-transfected. Groups consisted of untreated cells (three samples), and negative control (siNeg) transfected-TC32 cells (six samples), and TC32 cells in which either SUPT6H, SF3B1 or HNRNPH1 were silenced; three different siRNAs corresponding to each gene were assessed separately.

2016-01-15 | E-GEOD-67736 | biostudies-arrayexpress

Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival

Project description:Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival

| PRJNA666669 | ENA

Aberrant DNA methylation in rhabdomyosarcoma

Project description:Many pediatric malignancies are embryonal in nature, and one hypothesis for the origin of embryonal tumors is that they arise from a defect in differentiation, either by an inability to terminally differentiate or a reversion to a pluripotent state. There is emerging evidence that epigenetic regulation plays an important role in the transition from embryonic stem cell to a more committed cell fate, utilizing both de novo DNA methylation and poised M-bM-^@M-^XbivalentM-bM-^@M-^Y chromatin domains (H3K27me3 and H3K4me3) to abolish pluripotency and gain lineage- and cell-type-specific characteristics as a cell differentiates. Thus inappropriate epigenetic silencing by aberrant DNA methylation of bivalent genes required for differentiation could lead to the uncontrolled cell growth observed in cancer. Our broad hypothesis is that aberrant DNA methylation in cancer is targeted to a non-random subset of critical pathways used in normal development. This dysregulation of the normal epigenetic program used in development promotes cellular proliferation and provides a mechanism to block differentiation in pediatric cancers, such as rhabdomyosarcoma. Examination of DNA methylation in fourteen human rhabdomyosarcoma patient samples using RRBS. In addition, RRBS was used to examine DNA methylation in one human rhabdomyosarcoma cell line (RD) forced to terminally differentiate by expression of the forced heterodimer MyoD~E12 (MDE). Lastly, RRBS was used to examine DNA methylation changes during normal differentiation in one primary human normal myoblast cell line

2014-10-22 | E-GEOD-61150 | biostudies-arrayexpress

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma

2016-01-15 | GSE67736 | GEO